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Abstract
There have recently been significant changes in diagnostic practices for detecting enterovirus (EV) infections across England and Wales.
Reports of laboratory-confirmed EV infections submitted by National Health Service (NHS) hospital laboratories to Public Health England
(PHE) over a 12-year period (2000–2011) were analysed. Additionally, the PHE Virus Reference Department (VRD) electronic database
containing molecular typing data from 2004 onwards was interrogated. Of the 13 901 reports, there was a decline from a peak of 2254 in
2001 to 589 in 2006, and then an increase year-on-year to 1634 in 2011. This increase coincided with increasing PCR-based laboratory
diagnosis, which accounted for 36% of reported cases in 2000 and 92% in 2011. The estimated annual incidence in 2011 was 3.9/100 000
overall and 238/100 000 in those aged <3 months, who accounted for almost one-quarter of reported cases (n = 2993, 23%). During 2004–
2011, 2770 strains were submitted for molecular typing to the VRD, who found no evidence for a predominance of any particular strain.
Thus, the recent increase in reported cases closely reflects the increase in PCR testing by NHS hospitals, but is associated with a lower
proportion of samples being submitted for molecular typing. The high EV rate in young infants merits further investigation to inform
evidence-based management guidance.
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Introduction
The widespread introduction of highly effective conjugate
vaccines in industrialized countries has led to a significant
reduction in the burden of serious bacterial infections across
all age groups through direct and indirect (herd) protection
[1,2]. As a consequence, most individuals with central nervous
system infections now have aseptic meningitis [3,4], which is
usually of viral aetiology [5,6]. In children, aseptic meningitis
now accounts for >90% of meningitis cases [3,7], and c. 85% of
these are caused by enteroviruses (EVs) [5].
Almost 100 EV types have been identified, accounting for
30 000–50 000 annual hospital admissions in the USA, mainly
for aseptic meningitis [8]. The vast majority of EV infections
occur in children aged <5 years, with one-third of cases being
diagnosed in infants aged <12 months [9,10]. The clinical
manifestations of EV infection vary from non-specific febrile
illnesses and respiratory symptoms to serious presentations
including meningitis, encephalitis, myocarditis, hepatitis, and
potentially fatal multi-organ failure [11].
With the increasing availability of PCR testing, many
hospital laboratories no longer perform viral cultures rou-
tinely. PCR testing is cheaper, rapid, requires small amounts of
biological material, can be used for multiple pathogens, and can
detect almost all EV types, because the viruses share common
genetic sequences. For EVs, PCR has greater sensitivity and
specificity than viral cultures [12–15]. Data from these studies
show that it is possible to deliver a result within 5–6 h of
sample testing, which could, in turn, deliver significant cost
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savings by reducing unnecessary antimicrobial use and short-
ening hospital stays.
PCR testing, however, requires clinicians to specifically
request PCR testing for EVs, and strains need to be submitted
to reference centres for molecular typing. At a national level,
EV surveillance is important to identify emerging strains, link
EV types with clinical patterns of disease, and help develop
evidence-based guidance to manage EV infections, including the
need for new therapies. This study aimed to describe the
epidemiology of laboratory-confirmed EV infections in England
and Wales over a 12-year period, with particular emphasis on
the impact of changing diagnostic practices within National
Health Service (NHS) hospital laboratories in recent years.
Methods
NHS hospitals in England and Wales provide free and
unrestricted medical care for the entire population of
c. 55 million individuals, and their microbiology laboratories
routinely report clinically significant infections electronically on
a voluntary basis to Public Health England (PHE) using
LabBase2, which is subject to weekly audits of participation
and data quality. For this study, demographic (age, gender, and
geographical region) and strain-specific (sample type, diagnos-
tic method, date of detection, and serotype) records of all
positive EV strains from different biological sites (blood,
cerebrospinal fluid (CSF), gastrointestinal or respiratory)
during 2000–2011 were extracted from LabBase2, de-dupli-
cated, and analysed. Reporting of the same pathogen from a
patient within 14 days was considered to be a single episode.
As part of the PHE’s active polio surveillance commitment
to the WHO, NHS laboratories are requested to submit all
positive EV strains to the PHE Virus Reference Department
(VRD) for confirmation and molecular typing, as described
previously [16]. This is offered as a free national service.
Typing results are reported back to the laboratories, but are
often not entered into the local database, and so molecular
data are rarely captured in LabBase2. We therefore interro-
gated the VRD electronic database, which contains molecular
typing data for all submitted strains from 2004 onwards.
LabBase2 and the VRD database are two exclusive datasets.
Data analysis
Data were analysed with STATA, v.11 (StataCorp, College
Station, TX, USA). Cases were categorized into the following
age groups: 0–3 months, 3–11 months, 1–4 years, 5–14 years,
15–24 years, 25–44 years, 45–64 years, and ≥65 years. Cate-
gorical variables were expressed as proportions, and com-
pared by use of the chi-square test or Fisher exact test, as
appropriate. Age-specific incidence was calculated from
mid-year population estimates obtained from the Office for
National Statistics (www.statistics.gov.uk).
Results
During 2000–2011, a total of 13 901 laboratory-confirmed EV
cases were reported in England and Wales (mean annual
incidence, 2.9/100 000). The number of reports increased
from 2000 to 2001, and then declined to its lowest level in
2006, before increasing year-on-year until 2011 (Fig. 1). These
changes occurred proportionally across all age groups, with no
particular age group dominating during the 12-year surveillance
period (Fig. 1). The characteristic seasonal trends in EV—
peaks in the summer and troughs in the winter—were
observed only during periods of high incidence in 2000 and
2010 (Fig. 2).
Over the 12-year period, the proportion of samples
confirmed by PCR increased rapidly from 36% in 2000 to
92% in 2011 (45% overall), whereas diagnosis by culture (53%
in 2000 to 31% in 2006 and 3% in 2011), microscopy (3% in
2000 to 0% in 2011) and serology (8% in 2000 to 2% in 2011)
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FIG. 1. Age distribution of laboratory-confirmed enterovirus infections in England and Wales during 2000–2011 obtained from LabBase 2.
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13 114 (94%) cases with age reported, the median age at
diagnosis was 4.0 years (interquartile range 0.3–28.5 years).
More than half (n = 7606, 58%) were diagnosed in children
(<15 years). The incidence was significantly higher in children
than in adults (7.0/100 000 vs. 1.4/100 000; p <0.0005). In
particular, young infants (<3 months) accounted for 23% of all
EV infections and 37% of childhood EV infections, and had the
highest incidence of EV infection (Table 1). After this age, the
incidence declined rapidly, with a smaller peak among those
aged 25–44 years (Table 1).
In contrast to changes in the methods used for EV detection,
the sources of the samples tested and subsequently reported
through LabBase 2 remained constant, with CSF accounting for
36% of samples (n = 5032), respiratory specimens for 26%
(n = 3563), gastrointestinal specimens for 17% (n = 2394), and
blood specimens for 12% (n = 1602). The proportion of
CSF-positive cases, however, was higher in some age groups:
25–44 years (64%), 15–24 years (57%), and <3 months (46%).
Molecular typing results were recorded in LabBase2 for
only 28% (3921/13901) of EV strains, and the proportion of
reports with typing results declined with age and over time. Of
the typed strains, 55% (n = 2143) were echoviruses, 23%
(n = 904) Coxsackie B, 5% (n = 194) Coxsackie A, 0.9%
(n = 351) EV type 70, and 0.6% (n = 24) EV type 71 (Fig. 4).
Nearly all polioviruses were detected in infants aged
<3 months (283/560, 51%) or toddlers (232/560, 41%), and
all were confirmed by the VRD to be the oral poliovirus
vaccine (OPV) strain. The last vaccine-related poliovirus
infection was detected in 2007.
The 2000–2001 peak was attributable to an echovirus 13
outbreak, accounting for 62% (459/742) and 73% (774/1066) of
strains typed in 2000 and 2001, respectively. The increasing
PCR diagnosis of clinical specimens coincided with a lower
proportion of molecular typing data for EV in LabBase2. The
proportion of strains without typing information in LabBase2
increased from 72% (424/588) in 2006 to 94% (1540/1633) in
2011. More complete genotyping data were available from the
VRD database. Table 2 summarizes the source of clinical
specimen by EV type. During 2004–2011, 2770 strains
underwent molecular typing, although typing failed for 32%
(895/2770 strains), usually because of small sample volumes or
low viral loads (Table 3). The available typing data suggest
natural fluctuations in circulating EV strains, with no evidence
of predominance of any particular EV strain over the course of
the surveillance period. Echoviruses were the predominant
group for several years (2004, 2009, and 2011).
Discussion
This study is the first to report the impact of changing
diagnostic practices for EV detection in England and Wales
since 1994 [9]. Currently, very few NHS laboratories perform
light/electron microscopy or viral cell culture, and most EV
cases are diagnosed by PCR. The increase in EV reporting in
recent years closely reflects the increase in PCR testing, which
was also associated with a lower proportion of samples being
submitted to the national reference department for confirma-
tion and typing. The high sensitivity of PCR as compared with
cell culture will also have contributed to the number of
laboratory-confirmed cases [12–15], and this trend is likely to
continue as more sensitive multiplex assays for simultaneous
detection of multiple pathogens in biological samples are
adopted by local hospitals. In addition to being cheap, rapid,
and sensitive, PCR testing for EV can directly impact on
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FIG. 2. Enterovirus seasonal trends in England and Wales during 2000–2011 obtained from LabBase 2.
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and shortening hospital stays. A study in Marseille, for
example, demonstrated that, following the introduction of
routine PCR testing, durations of hospitalization were reduced
from 5.4 days to 2.2 days during two separate outbreaks of EV
type 30, resulting in an estimated cost-saving of €322 000 [17].
Interrogation of two national datasets contemporaneously
allowed us to determine the proportion of samples being
submitted for molecular typing nationally. Whereas the
increase in PCR testing within NHS hospital microbiology
laboratories has improved EV diagnosis in recent years, the
proportion of strains with molecular typing data in LabBase2
has declined significantly. Typing information held by the VRD,
however, showed that the absolute number of strains under-
going molecular typing increased from 113 in 2004 to 698 in
2011. This increase was, in part, attributable to active efforts
by the VRD to increase submission rates from NHS labora-
tories as part of polio surveillance.
In 2000–2001, the UK, other European countries, Australia
and the USA experienced an outbreak of echovirus infection,
with echovirus 13 dominating in 2000 and echovirus 30 in
2001 [18,19]. Echovirus 30 is one of the more common
echovirus genotypes; it causes outbreaks every few years, and
causes mainly meningoencephalitis in children and adults, with
varying clinical severity [20]. Echovirus 13 is a rare genotype
that was responsible for major global outbreaks in the early
2000s [18,21]. The UK was declared free of wild poliovirus in
1998, and Europe followed suit in 2002. In 2004, the UK
switched from live OPV to inactivated poliovirus vaccine in the
infant immunization schedule. In England and Wales, the VRD
plays a key role in investigating all polioviruses identified by
NHS laboratories as part of ongoing polio elimination surveil-
lance, to ensure that that these are not wild-type polioviruses
or neurovirulent, vaccine-derived strains. In recent years, the
detected strains have usually been from children from
overseas who had recently received an OPV. In the past
12 months, however, there have been reports of polio in nine
countries, with 68 cases being recorded in the first months of
2014 as compared with 24 cases in the same period of 2013
[22]. In May this year, the WHO declared the spread of polio
to be an international public health emergency, thus highlight-
ing the need for ongoing active national polio surveillance.
In the UK and the USA, surveillance data from the 1980s
to 2005 have shown annual fluctuations in circulating EV
types, with a seasonal variation [8–10]. Coxsackie A9 and B2,
along with echoviruses 3, 7, 13, and 16, have all shown annual
peaks and troughs in different years [8,9]. Neither molecular
typing results in LabBase2 or the VRD data indicate a
predominance of any particular EV type in recent years,
suggesting that the observed increase in EV reports most
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laboratories rather than a true increase in disease rates.
Among other European countries, during 2000–2007, Finland
identified echoviruses 11 and 6 along with Coxsackie A24,
B5 and B4 as the five most common EV types circulating [23].
This study included both clinical and environmental samples,
and did not describe any temporal trends, but reported that
molecular typing of isolates by partial VP1 sequencing was
quick and reliable. The study isolated Coxsackie A24 strains,
mostly from stool samples obtained from immigrants, and
thus thought to be imported infections rather than evidence
of endemic circulation. In The Netherlands, national
surveillance during 1996–2011 showed a gradual increase in
EV-positive stool samples, from 6.5% in 2007 to 10.8% in
2011, with a higher proportion of positive reports being
recorded by laboratories using molecular assays than by
laboratories using cell culture [24]. The authors noted an
increase in untyped reports coinciding with the introduction
of molecular EV diagnosis [24]. This is consistent with the
findings of our study.
Although the clinical spectra of diseases associated with EV
types overlap, some manifestations of EV infection are
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FIG. 4. Enterovirus types (including untyped strains) circulating in England and Wales during 2000–2011, obtained from LabBase2. Note:
enterovirus type was not reported because it was not sent to the Virus Reference Department (VRD) or because LabBase2 was not updated after
results from the VRD had been reported to the local National Health Service hospital laboratory.
TABLE 2. Enterovirus strains by biological site of detection (no. (%)) submitted to the Public Health England national Virus
Reference Department during 2004–2011; biological site was reported for 1875 of 1875 (100%) typed enterovirus strains
Blood CSF Gastrointestinal Respiratory Skin Tissue Total
Coxsackie A 7 (2) 87 (22) 131 (33) 81 (20) 42 (10) 52 (13) 400 (100)
Coxsackie B 14 (3) 98 (22) 108 (25) 58 (13) 5 (1) 159 (36) 442 (100)
Echovirus 17 (2) 411 (45) 202 (22) 64 (7) 3 (1) 216 (23) 913 (100)
Enterovirus 3 (3) 17 (14) 52 (43) 28 (23) 2 (2) 18 (15) 120 (100)
Total 41 (2) 613 (33) 493 (26) 231 (12) 52 (3) 445 (24) 1875 (100)
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with echovirus 30, hand-foot-and-mouth disease with Cox-
sackie A16, and acute haemorrhagic conjunctivitis with EV
type 70 and Coxsackie A24) [10]. The recent Californian
outbreak of EV type 68 over a 100-mile radius may have
caused acute flaccid paralysis in up to 20 children over an
18-month period. EV type 68 was isolated from the stools of
five children with acute flaccid paralysis, but the lack of active
prospective clinical and microbiological surveillance data made
it difficult to establish causality [25], emphasizing the impor-
tance of active surveillance to monitor emerging serotypes in
order to inform public health management. EV type 71 vaccine
trials conducted in China, for example, were performed as a
consequence of active surveillance identifying an increased
burden of EV type 71 disease prompting urgent preventive
action, and recent EV type 71 vaccine trials have shown
promising safety, efficacy and immunogenicity results in infants
and young children [26,27].
The EV incidence in infants aged <3 months was almost
100-fold higher than the overall rate; this is far higher than the
rates for bacterial infections in this age group [28,29]. In
northern Finland, the annual incidence of bacterial central
nervous system infections was 36.3/100 000, as compared
with 688/100 000 for viral infection [30]. Comparison of rates
is complicated by differences in country-specific clinical
practice (e.g. threshold for investigating and hospitalizing
patients with suspected viral infections), investigation (e.g.
threshold for performing lumbar puncture), and diagnosis (e.g.
availability of routine viral cultures or PCR testing). Interest-
ingly, characteristic summer peaks associated with EV infec-
tions (cases increasing in April, peaking in July, and declining by
September) [8–10] were observed mainly in years with a large
number of cases reported, highlighting the importance of
considering EV infection throughout the year and not only in
the summer months.
TABLE 3. Enterovirus strains submitted to the Public Health England national Virus Reference Department for confirmation
and typing during 2004–2011; untypeable strains were mostly attributable to low sample volumes submitted and/or low viral loads
Year 2004 2005 2006 2007 2008 2009 2010 2011 Total
Total submitted 113 224 359 218 346 412 400 698 2770
Untyped 15 83 162 100 45 64 207 219 895
Typed 98 141 197 118 301 348 193 479 1875
Coxsackie A1 – – – – 1 – – – 1
Coxsackie A2 – – 1 2 5 3 7 11 29
Coxsackie A4 – 2 1 – 8 4 7 5 27
Coxsackie A5 – – – – 3 3 – – 6
Coxsackie A6 – 1 2 4 8 18 8 34 75
Coxsackie A8 – – – – – – – 4 4
Coxsackie A9 10 7 5 5 24 3 40 3 97
Coxsackie A10 – – – 2 4 32 4 4 46
Coxsackie A13 – – – – 1 – – – 1
Coxsackie A15 – – – 1 – – – – 1
Coxsackie A16 3 3 8 3 8 12 3 47 87
Coxsackie A17 – – – – – – – 1 1
Coxsackie A19 – – – – 1 – – 1 2
Coxsackie A21 3 1 13 – – – 1 – 18
Coxsackie A22 – 1 – – – – – – 1
Coxsackie A24 – 1 – 2 – – 1 – 4
Coxsackie B1 – – 1 13 1 2 9 5 31
Coxsackie B2 2 7 6 12 18 12 5 45 107
Coxsackie B3 4 26 4 1 39 4 19 4 101
Coxsackie B4 12 4 11 6 13 19 4 40 109
Coxsackie B5 – 33 4 – 4 18 2 33 94
Echovirus 2 – – 1 – – – – 1 2
Echovirus 3 5 6 – 3 4 – – 8 26
Echovirus 4 – – – – 1 – 4 – 5
Echovirus 5 4 2 – – – – – 4 10
Echovirus 6 2 – 39 5 5 18 13 11 93
Echovirus 7 – 10 2 2 11 7 – 42 74
Echovirus 8 – 2 – – – 1 – – 3
Echovirus 9 20 – – 13 4 38 1 28 104
Echovirus 11 – – 25 10 8 11 4 58 116
Echovirus 13 – – 6 – – 1 1 1 9
Echovirus 14 1 – – – 4 – – 3 8
Echovirus 15 – – – – – 1 1 – 2
Echovirus 16 12 3 1 – – 4 – – 20
Echovirus 17 – – 1 1 – 3 3 3 11
Echovirus 18 – 1 34 7 10 101 – 16 169
Echovirus 21 – – 1 – – – – 1 2
Echovirus 25 12 26 4 16 18 6 21 4 107
Echovirus 27 – 1 – – 1 – 1 – 3
Echovirus 30 – – 12 9 58 13 3 35 130
Echovirus 31 – – – – – 1 – 1 2
Echovirus 33 – – – – – – – 17 17
Enterovirus 68 2 – – – – 10 2 – 14
Enterovirus 71 6 3 15 1 37 3 29 8 102
Enterovirus 76 – – – – – – – 1 1
Enterovirus 85 – 1 – – – – – – 1
Enterovirus 90 – – – – 2 – – – 2
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Our analysis has some limitations. Comparison of voluntary
reporting through LabBase2 with mandatory national health-
care-associated infection reporting systems resulted in an
estimated 75% completeness of reporting in 2003, rising to
83% in 2010 [31]. LabBase2 also lacks denominator data,
because negative results are not reported. It was therefore not
possible to assess the contribution of any changes in clinical
practice following national recommendations, such as the
NICE guidelines in 2007 encouraging lumbar punctures for
young infants with fever (http://guidance.nice.org.uk/CG160).
There are also no data on the diagnostic testing offered by
NHS laboratories or criteria for EV testing for submitted
samples. As a consequence, it was not possible to assess how
the availability of different diagnostic tests changed over time,
or what proportion of laboratories currently offer routine
PCR testing. Another limitation of LabBase2 was the lack of
clinical and outcome data. Although isolation of EVs from CSF
is likely to indicate viral meningitis, a patient with clinical or
laboratory (e.g. CSF lymphocytosis) evidence of viral menin-
gitis but in whom EV was isolated from another site
(e.g. throat, stool), for example, may not be identified as a
case of EV meningitis in LabBase2.
In conclusion, the increasing trend in EV diagnosis highlights
the need to systematically collect more detailed clinical data
for laboratory-confirmed cases to provide an evidence base
for informing national guidance for the clinical management
and investigation of individuals with suspected EV infection. In
particular, there is a need to provide higher-quality and more
accurate quantitative data on the true burden of EV infections
and subsequent long-term outcomes.
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Additional Supporting Information may be found in the online
version of this article:
Table S1. Enterovirus strains by biological site of detection
submitted to the Public Health England national Virus
Reference Department during 2004–2011 can be found as
supplementary data (Table S1).
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